Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-08-29

AUTHORS

Virginia Martín, Josep Vidal, Samuel J. P. Malkin, Nino Hallén, Barnaby Hunt

ABSTRACT

IntroductionHealthcare systems aim to maximize the health of the population, but must work within constrained budgets. Therefore, choosing therapies that are both effective and cost-effective is paramount. The present analysis assessed the cost-effectiveness of once-weekly semaglutide 0.5 mg and 1 mg versus once-weekly dulaglutide 1.5 mg and versus once daily sitagliptin 100 mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on oral anti-hyperglycemic medications over patient lifetimes from a healthcare payer perspective in the Spanish setting.MethodsCost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model. Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2). Captured costs included treatment costs and costs of diabetes-related complications. Projected outcomes were discounted at 3.0% annually.ResultsProjections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.02 and 0.11 years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11 quality-adjusted life years (QALYs), respectively, versus dulaglutide 1.5 mg. Compared with sitagliptin, once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.17 and 0.24 years, respectively and discounted quality-adjusted life expectancy of 0.16 and 0.23 QALYs. The increased duration and quality of life with once-weekly semaglutide 0.5 mg and 1 mg resulted from a reduced cumulative incidence and delayed time to onset of diabetes-related complications. Avoided complications resulted in once-weekly semaglutide 0.5 mg and 1 mg being cost-saving versus dulaglutide 1.5 mg and versus sitagliptin 100 mg from a healthcare payer perspective.ConclusionsOnce-weekly semaglutide 0.5 mg and 1 mg were considered dominant (more effective and less costly) versus sitagliptin 100 mg and dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on oral anti-hyperglycemic medications and are likely to be a good use of healthcare resources in the Spanish setting. More... »

PAGES

4427-4445

References to SciGraph publications

  • 2011-10-11. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study in DIABETOLOGIA
  • 2013-06-22. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82 in DIABETOLOGIA
  • 2020-01-10. The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain in DIABETES THERAPY
  • 2013-06-03. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries in HEALTH AND QUALITY OF LIFE OUTCOMES
  • 2019-06-05. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia in ADVANCES IN THERAPY
  • 2014-05-17. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries in QUALITY OF LIFE RESEARCH
  • 2019-05-16. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting in DIABETES THERAPY
  • 2013-10-17. Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin in DIABETES THERAPY
  • 2004-10-27. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) in DIABETOLOGIA
  • 2015-03-06. Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin in DIABETES THERAPY
  • 2017-02-21. Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain in DIABETES THERAPY
  • 2014-12-18. Economic evaluation of implementation strategies in health care in IMPLEMENTATION SCIENCE
  • 2002-06-12. Assessing the impact of complications on the costs of Type II diabetes in DIABETOLOGIA
  • 2018-10-05. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) in DIABETOLOGIA
  • 2019-03-29. Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada in PHARMACOECONOMICS - OPEN
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12325-020-01464-1

    DOI

    http://dx.doi.org/10.1007/s12325-020-01464-1

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1130447928

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/32862365


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cost-Benefit Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diabetes Mellitus, Type 2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glucagon-Like Peptides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hypoglycemic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoglobulin Fc Fragments", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Quality of Life", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Recombinant Fusion Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sitagliptin Phosphate", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Novo Nordisk Pharma SA, Madrid, Spain", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Novo Nordisk Pharma SA, Madrid, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mart\u00edn", 
            "givenName": "Virginia", 
            "id": "sg:person.013364144073.37", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013364144073.37"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM), Barcelona, Spain", 
              "id": "http://www.grid.ac/institutes/grid.430579.c", 
              "name": [
                "Endocrinology and Nutrition Department, Hospital Cl\u00ednic, Barcelona, Spain", 
                "Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM), Barcelona, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Vidal", 
            "givenName": "Josep", 
            "id": "sg:person.01132216032.56", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132216032.56"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Ossian Health Economics and Communications, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Malkin", 
            "givenName": "Samuel J. P.", 
            "id": "sg:person.012067446720.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Novo Nordisk A/S, S\u00f8borg, Denmark", 
              "id": "http://www.grid.ac/institutes/grid.425956.9", 
              "name": [
                "Novo Nordisk A/S, S\u00f8borg, Denmark"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hall\u00e9n", 
            "givenName": "Nino", 
            "id": "sg:person.07745024772.02", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07745024772.02"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Ossian Health Economics and Communications, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hunt", 
            "givenName": "Barnaby", 
            "id": "sg:person.01346701147.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00125-018-4729-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1107409514", 
              "https://doi.org/10.1007/s00125-018-4729-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1477-7525-11-90", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013049175", 
              "https://doi.org/10.1186/1477-7525-11-90"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-013-2940-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010988781", 
              "https://doi.org/10.1007/s00125-013-2940-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13012-014-0168-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015762781", 
              "https://doi.org/10.1186/s13012-014-0168-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11136-014-0712-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041603789", 
              "https://doi.org/10.1007/s11136-014-0712-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-011-2336-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036112369", 
              "https://doi.org/10.1007/s00125-011-2336-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-004-1527-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036304902", 
              "https://doi.org/10.1007/s00125-004-1527-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-013-0044-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003457712", 
              "https://doi.org/10.1007/s13300-013-0044-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-015-0103-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001558391", 
              "https://doi.org/10.1007/s13300-015-0103-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-017-0239-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083855326", 
              "https://doi.org/10.1007/s13300-017-0239-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s41669-019-0131-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1113109417", 
              "https://doi.org/10.1007/s41669-019-0131-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12325-019-00965-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1116668545", 
              "https://doi.org/10.1007/s12325-019-00965-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-002-0859-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027149253", 
              "https://doi.org/10.1007/s00125-002-0859-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-019-00751-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1124008055", 
              "https://doi.org/10.1007/s13300-019-00751-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-019-0630-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1114500568", 
              "https://doi.org/10.1007/s13300-019-0630-6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2020-08-29", 
        "datePublishedReg": "2020-08-29", 
        "description": "IntroductionHealthcare systems aim to maximize the health of the population, but must work within constrained budgets. Therefore, choosing therapies that are both effective and cost-effective is paramount. The present analysis assessed the cost-effectiveness of once-weekly semaglutide 0.5\u00a0mg and 1\u00a0mg versus once-weekly dulaglutide 1.5\u00a0mg and versus once daily sitagliptin 100\u00a0mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on oral anti-hyperglycemic medications over patient lifetimes from a healthcare payer perspective in the Spanish setting.MethodsCost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model. Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5\u00a0mg and 1\u00a0mg, dulaglutide 1.5\u00a0mg and sitagliptin 100\u00a0mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2). Captured costs included treatment costs and costs of diabetes-related complications. Projected outcomes were discounted at 3.0% annually.ResultsProjections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5\u00a0mg and 1\u00a0mg were associated with improvements in discounted life expectancy of 0.02 and 0.11\u00a0years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11\u00a0quality-adjusted life years (QALYs), respectively, versus dulaglutide 1.5\u00a0mg. Compared with sitagliptin, once-weekly semaglutide 0.5\u00a0mg and 1\u00a0mg were associated with improvements in discounted life expectancy of 0.17 and 0.24\u00a0years, respectively and discounted quality-adjusted life expectancy of 0.16 and 0.23\u00a0QALYs. The increased duration and quality of life with once-weekly semaglutide 0.5\u00a0mg and 1\u00a0mg resulted from a reduced cumulative incidence and delayed time to onset of diabetes-related complications. Avoided complications resulted in once-weekly semaglutide 0.5\u00a0mg and 1\u00a0mg being cost-saving versus dulaglutide 1.5 mg and versus sitagliptin 100\u00a0mg from a healthcare payer perspective.ConclusionsOnce-weekly semaglutide 0.5\u00a0mg and 1\u00a0mg were considered dominant (more effective and less costly) versus sitagliptin 100\u00a0mg and dulaglutide 1.5\u00a0mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on oral anti-hyperglycemic medications and are likely to be a good use of healthcare resources in the Spanish setting.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s12325-020-01464-1", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1096634", 
            "issn": [
              "0741-238X", 
              "1865-8652"
            ], 
            "name": "Advances in Therapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "10", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "37"
          }
        ], 
        "keywords": [
          "weekly semaglutide 0.5", 
          "quality-adjusted life years", 
          "oral anti-hyperglycemic medications", 
          "anti-hyperglycemic medications", 
          "inadequate glycemic control", 
          "diabetes-related complications", 
          "sitagliptin 100", 
          "treatment of patients", 
          "type 2 diabetes", 
          "healthcare payer perspective", 
          "quality-adjusted life expectancy", 
          "dulaglutide 1.5", 
          "glycemic control", 
          "clinical outcomes", 
          "life expectancy", 
          "patient's lifetime", 
          "payer perspective", 
          "long-term clinical outcomes", 
          "weekly dulaglutide 1.5", 
          "Spanish setting", 
          "Baseline cohort characteristics", 
          "clinical trial program", 
          "quality of life", 
          "cumulative incidence", 
          "IQVIA CORE", 
          "cohort characteristics", 
          "trial program", 
          "healthcare resources", 
          "life years", 
          "complications", 
          "treatment costs", 
          "dulaglutide", 
          "treatment effects", 
          "medications", 
          "patients", 
          "diabetes", 
          "sitagliptin", 
          "outcomes", 
          "expectancy", 
          "treatment", 
          "years", 
          "long term", 
          "setting", 
          "projected outcome", 
          "therapy", 
          "incidence", 
          "control", 
          "onset", 
          "health", 
          "MethodsCosts", 
          "duration", 
          "Versus", 
          "improvement", 
          "population", 
          "initiation", 
          "present analysis", 
          "evaluation", 
          "life", 
          "effect", 
          "use", 
          "program", 
          "quality", 
          "time", 
          "analysis", 
          "cost", 
          "characteristics", 
          "better use", 
          "perspective", 
          "constrained budget", 
          "model", 
          "system", 
          "resources", 
          "lifetime", 
          "core", 
          "budget"
        ], 
        "name": "Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting", 
        "pagination": "4427-4445", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1130447928"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12325-020-01464-1"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "32862365"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12325-020-01464-1", 
          "https://app.dimensions.ai/details/publication/pub.1130447928"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T21:06", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_861.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s12325-020-01464-1"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-020-01464-1'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-020-01464-1'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-020-01464-1'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-020-01464-1'


     

    This table displays all metadata directly associated to this object as RDF triples.

    269 TRIPLES      21 PREDICATES      124 URIs      101 LITERALS      16 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12325-020-01464-1 schema:about N0fc9c11571c147fba192c45415d3c076
    2 N48788c84bbd94317a48a94d5a8e04341
    3 Nb35ed68f0dab445489b66c497006792c
    4 Nc333a06e15b84c7e9298d3628cf10819
    5 Nc513dd31a41f4513ba4dda4c4b357796
    6 Ncfec8bd8234f45ba9a8d6fdf2c8eef1e
    7 Nddf3cb4e740c4f09a7a6386af94ecd18
    8 Ne9ff3673d1b5491e98d74f7281dd71c4
    9 Nf320c6bc776a46c882841f1b161b3230
    10 anzsrc-for:11
    11 anzsrc-for:1103
    12 schema:author Ne10128fd56a7432e828275b94c316cbb
    13 schema:citation sg:pub.10.1007/s00125-002-0859-9
    14 sg:pub.10.1007/s00125-004-1527-z
    15 sg:pub.10.1007/s00125-011-2336-9
    16 sg:pub.10.1007/s00125-013-2940-y
    17 sg:pub.10.1007/s00125-018-4729-5
    18 sg:pub.10.1007/s11136-014-0712-x
    19 sg:pub.10.1007/s12325-019-00965-y
    20 sg:pub.10.1007/s13300-013-0044-9
    21 sg:pub.10.1007/s13300-015-0103-5
    22 sg:pub.10.1007/s13300-017-0239-6
    23 sg:pub.10.1007/s13300-019-00751-7
    24 sg:pub.10.1007/s13300-019-0630-6
    25 sg:pub.10.1007/s41669-019-0131-6
    26 sg:pub.10.1186/1477-7525-11-90
    27 sg:pub.10.1186/s13012-014-0168-y
    28 schema:datePublished 2020-08-29
    29 schema:datePublishedReg 2020-08-29
    30 schema:description IntroductionHealthcare systems aim to maximize the health of the population, but must work within constrained budgets. Therefore, choosing therapies that are both effective and cost-effective is paramount. The present analysis assessed the cost-effectiveness of once-weekly semaglutide 0.5 mg and 1 mg versus once-weekly dulaglutide 1.5 mg and versus once daily sitagliptin 100 mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on oral anti-hyperglycemic medications over patient lifetimes from a healthcare payer perspective in the Spanish setting.MethodsCost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model. Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2). Captured costs included treatment costs and costs of diabetes-related complications. Projected outcomes were discounted at 3.0% annually.ResultsProjections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.02 and 0.11 years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11 quality-adjusted life years (QALYs), respectively, versus dulaglutide 1.5 mg. Compared with sitagliptin, once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.17 and 0.24 years, respectively and discounted quality-adjusted life expectancy of 0.16 and 0.23 QALYs. The increased duration and quality of life with once-weekly semaglutide 0.5 mg and 1 mg resulted from a reduced cumulative incidence and delayed time to onset of diabetes-related complications. Avoided complications resulted in once-weekly semaglutide 0.5 mg and 1 mg being cost-saving versus dulaglutide 1.5 mg and versus sitagliptin 100 mg from a healthcare payer perspective.ConclusionsOnce-weekly semaglutide 0.5 mg and 1 mg were considered dominant (more effective and less costly) versus sitagliptin 100 mg and dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on oral anti-hyperglycemic medications and are likely to be a good use of healthcare resources in the Spanish setting.
    31 schema:genre article
    32 schema:isAccessibleForFree true
    33 schema:isPartOf N2032a10b0df9414682d75f007f23aa46
    34 N283e43a70ef74544a43aa24acd19ad27
    35 sg:journal.1096634
    36 schema:keywords Baseline cohort characteristics
    37 IQVIA CORE
    38 MethodsCosts
    39 Spanish setting
    40 Versus
    41 analysis
    42 anti-hyperglycemic medications
    43 better use
    44 budget
    45 characteristics
    46 clinical outcomes
    47 clinical trial program
    48 cohort characteristics
    49 complications
    50 constrained budget
    51 control
    52 core
    53 cost
    54 cumulative incidence
    55 diabetes
    56 diabetes-related complications
    57 dulaglutide
    58 dulaglutide 1.5
    59 duration
    60 effect
    61 evaluation
    62 expectancy
    63 glycemic control
    64 health
    65 healthcare payer perspective
    66 healthcare resources
    67 improvement
    68 inadequate glycemic control
    69 incidence
    70 initiation
    71 life
    72 life expectancy
    73 life years
    74 lifetime
    75 long term
    76 long-term clinical outcomes
    77 medications
    78 model
    79 onset
    80 oral anti-hyperglycemic medications
    81 outcomes
    82 patient's lifetime
    83 patients
    84 payer perspective
    85 perspective
    86 population
    87 present analysis
    88 program
    89 projected outcome
    90 quality
    91 quality of life
    92 quality-adjusted life expectancy
    93 quality-adjusted life years
    94 resources
    95 setting
    96 sitagliptin
    97 sitagliptin 100
    98 system
    99 therapy
    100 time
    101 treatment
    102 treatment costs
    103 treatment effects
    104 treatment of patients
    105 trial program
    106 type 2 diabetes
    107 use
    108 weekly dulaglutide 1.5
    109 weekly semaglutide 0.5
    110 years
    111 schema:name Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting
    112 schema:pagination 4427-4445
    113 schema:productId N6d12810192f24cb1aad4e3543a02e134
    114 N83f10325f0054878b5c753d451343723
    115 N95319935419646c2a14443eedf5a6209
    116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130447928
    117 https://doi.org/10.1007/s12325-020-01464-1
    118 schema:sdDatePublished 2022-11-24T21:06
    119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    120 schema:sdPublisher N99290bc932644ab9974d733378a42bc1
    121 schema:url https://doi.org/10.1007/s12325-020-01464-1
    122 sgo:license sg:explorer/license/
    123 sgo:sdDataset articles
    124 rdf:type schema:ScholarlyArticle
    125 N0fc9c11571c147fba192c45415d3c076 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Hypoglycemic Agents
    127 rdf:type schema:DefinedTerm
    128 N109a5135b7cf47fcbea5104f03e0f369 rdf:first sg:person.07745024772.02
    129 rdf:rest Na5125cb9d45742399139b4f91ace5e45
    130 N131a96a6239c4d1bb118511b91db09e6 rdf:first sg:person.012067446720.22
    131 rdf:rest N109a5135b7cf47fcbea5104f03e0f369
    132 N2032a10b0df9414682d75f007f23aa46 schema:issueNumber 10
    133 rdf:type schema:PublicationIssue
    134 N283e43a70ef74544a43aa24acd19ad27 schema:volumeNumber 37
    135 rdf:type schema:PublicationVolume
    136 N48788c84bbd94317a48a94d5a8e04341 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Diabetes Mellitus, Type 2
    138 rdf:type schema:DefinedTerm
    139 N6d12810192f24cb1aad4e3543a02e134 schema:name dimensions_id
    140 schema:value pub.1130447928
    141 rdf:type schema:PropertyValue
    142 N83f10325f0054878b5c753d451343723 schema:name doi
    143 schema:value 10.1007/s12325-020-01464-1
    144 rdf:type schema:PropertyValue
    145 N95319935419646c2a14443eedf5a6209 schema:name pubmed_id
    146 schema:value 32862365
    147 rdf:type schema:PropertyValue
    148 N99290bc932644ab9974d733378a42bc1 schema:name Springer Nature - SN SciGraph project
    149 rdf:type schema:Organization
    150 Na5125cb9d45742399139b4f91ace5e45 rdf:first sg:person.01346701147.33
    151 rdf:rest rdf:nil
    152 Nb35ed68f0dab445489b66c497006792c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Quality of Life
    154 rdf:type schema:DefinedTerm
    155 Nc333a06e15b84c7e9298d3628cf10819 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Glucagon-Like Peptides
    157 rdf:type schema:DefinedTerm
    158 Nc513dd31a41f4513ba4dda4c4b357796 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Sitagliptin Phosphate
    160 rdf:type schema:DefinedTerm
    161 Ncfec8bd8234f45ba9a8d6fdf2c8eef1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Recombinant Fusion Proteins
    163 rdf:type schema:DefinedTerm
    164 Nddf3cb4e740c4f09a7a6386af94ecd18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Cost-Benefit Analysis
    166 rdf:type schema:DefinedTerm
    167 Ne10128fd56a7432e828275b94c316cbb rdf:first sg:person.013364144073.37
    168 rdf:rest Ned99e16128964dcebdcfc75a63f3a6a7
    169 Ne9ff3673d1b5491e98d74f7281dd71c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Immunoglobulin Fc Fragments
    171 rdf:type schema:DefinedTerm
    172 Ned99e16128964dcebdcfc75a63f3a6a7 rdf:first sg:person.01132216032.56
    173 rdf:rest N131a96a6239c4d1bb118511b91db09e6
    174 Nf320c6bc776a46c882841f1b161b3230 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Humans
    176 rdf:type schema:DefinedTerm
    177 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    178 schema:name Medical and Health Sciences
    179 rdf:type schema:DefinedTerm
    180 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    181 schema:name Clinical Sciences
    182 rdf:type schema:DefinedTerm
    183 sg:journal.1096634 schema:issn 0741-238X
    184 1865-8652
    185 schema:name Advances in Therapy
    186 schema:publisher Springer Nature
    187 rdf:type schema:Periodical
    188 sg:person.01132216032.56 schema:affiliation grid-institutes:grid.430579.c
    189 schema:familyName Vidal
    190 schema:givenName Josep
    191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132216032.56
    192 rdf:type schema:Person
    193 sg:person.012067446720.22 schema:affiliation grid-institutes:None
    194 schema:familyName Malkin
    195 schema:givenName Samuel J. P.
    196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22
    197 rdf:type schema:Person
    198 sg:person.013364144073.37 schema:affiliation grid-institutes:None
    199 schema:familyName Martín
    200 schema:givenName Virginia
    201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013364144073.37
    202 rdf:type schema:Person
    203 sg:person.01346701147.33 schema:affiliation grid-institutes:None
    204 schema:familyName Hunt
    205 schema:givenName Barnaby
    206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33
    207 rdf:type schema:Person
    208 sg:person.07745024772.02 schema:affiliation grid-institutes:grid.425956.9
    209 schema:familyName Hallén
    210 schema:givenName Nino
    211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07745024772.02
    212 rdf:type schema:Person
    213 sg:pub.10.1007/s00125-002-0859-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027149253
    214 https://doi.org/10.1007/s00125-002-0859-9
    215 rdf:type schema:CreativeWork
    216 sg:pub.10.1007/s00125-004-1527-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036304902
    217 https://doi.org/10.1007/s00125-004-1527-z
    218 rdf:type schema:CreativeWork
    219 sg:pub.10.1007/s00125-011-2336-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036112369
    220 https://doi.org/10.1007/s00125-011-2336-9
    221 rdf:type schema:CreativeWork
    222 sg:pub.10.1007/s00125-013-2940-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1010988781
    223 https://doi.org/10.1007/s00125-013-2940-y
    224 rdf:type schema:CreativeWork
    225 sg:pub.10.1007/s00125-018-4729-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107409514
    226 https://doi.org/10.1007/s00125-018-4729-5
    227 rdf:type schema:CreativeWork
    228 sg:pub.10.1007/s11136-014-0712-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041603789
    229 https://doi.org/10.1007/s11136-014-0712-x
    230 rdf:type schema:CreativeWork
    231 sg:pub.10.1007/s12325-019-00965-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1116668545
    232 https://doi.org/10.1007/s12325-019-00965-y
    233 rdf:type schema:CreativeWork
    234 sg:pub.10.1007/s13300-013-0044-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003457712
    235 https://doi.org/10.1007/s13300-013-0044-9
    236 rdf:type schema:CreativeWork
    237 sg:pub.10.1007/s13300-015-0103-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001558391
    238 https://doi.org/10.1007/s13300-015-0103-5
    239 rdf:type schema:CreativeWork
    240 sg:pub.10.1007/s13300-017-0239-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083855326
    241 https://doi.org/10.1007/s13300-017-0239-6
    242 rdf:type schema:CreativeWork
    243 sg:pub.10.1007/s13300-019-00751-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124008055
    244 https://doi.org/10.1007/s13300-019-00751-7
    245 rdf:type schema:CreativeWork
    246 sg:pub.10.1007/s13300-019-0630-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1114500568
    247 https://doi.org/10.1007/s13300-019-0630-6
    248 rdf:type schema:CreativeWork
    249 sg:pub.10.1007/s41669-019-0131-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113109417
    250 https://doi.org/10.1007/s41669-019-0131-6
    251 rdf:type schema:CreativeWork
    252 sg:pub.10.1186/1477-7525-11-90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013049175
    253 https://doi.org/10.1186/1477-7525-11-90
    254 rdf:type schema:CreativeWork
    255 sg:pub.10.1186/s13012-014-0168-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1015762781
    256 https://doi.org/10.1186/s13012-014-0168-y
    257 rdf:type schema:CreativeWork
    258 grid-institutes:None schema:alternateName Novo Nordisk Pharma SA, Madrid, Spain
    259 Ossian Health Economics and Communications, Basel, Switzerland
    260 schema:name Novo Nordisk Pharma SA, Madrid, Spain
    261 Ossian Health Economics and Communications, Basel, Switzerland
    262 rdf:type schema:Organization
    263 grid-institutes:grid.425956.9 schema:alternateName Novo Nordisk A/S, Søborg, Denmark
    264 schema:name Novo Nordisk A/S, Søborg, Denmark
    265 rdf:type schema:Organization
    266 grid-institutes:grid.430579.c schema:alternateName Centro de Investigación Biomédica en Red en Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain
    267 schema:name Centro de Investigación Biomédica en Red en Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain
    268 Endocrinology and Nutrition Department, Hospital Clínic, Barcelona, Spain
    269 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...